IBPL signs MOU with Viropro on molecule production

Ahmedabad, May 08 (UNI) Ahmedabad-based Intas Bio-pharmaceuticals Limited (IBPL) and Canada-based Viropro Inc signed a Memorandum of Understanding (MOU) to jointly explore the possibilities of production of an undisclosed molecule.

IBPL Director, Mani Iyer said that as part of the MOU, Viropro has developed certain proprietary technologies and sole expertise in a unique molecule dedicated towards bio-terapeutic products for which IBPL shall have non exclusive worldwide rights on the finished products.

The MOU also offers unique collaboration opportunities to both the companies for commercial as well as research interests. Both the companies are looking to enter into a contract to complete pre-clinical and clinical development as well as manufacture and commercially distribute the product based on the MOU. Additionally IBPL and Viropro desire to evaluate potential areas of collaboration in future for development of new molecules, he said.

Dr Jean-Marie Dupuy, President and CEO of Viropro, said ''we are pleased to be working with IBPL, a well established pharmaceuticals company that has a proven track record of quickly bringing products to market''.

Development of bio-generics including Cytokines, Hormones, Novel Products and recombinant blood factors is amongst the priority area for IBPL and Viropro. Both companies are constabltly exploring novel opportunities for undertaking research initiatives that will lead to expansion of their product portfolio, he said.

UNI